Was the omission of key data intentional or unintentional?
Apparatus
-
-
Apparatus
New Study Reveals Antibiotic Abuse For Sore Throats Pushes Up The Third Leading Cause Of Death Worldwide
Misconceptions about how to treat a sore throat are fuelling the overuse of antibiotics, according to STAR research.
-
Accelerating and simplifying the development and manufacturing process of cell and gene therapies.
-
Apparatus
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).
-
Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."
-
Apparatus
The Frontier Drug INT230-6 Has Shown Promising Therapeutic Results In Soft Tissue Sarcoma!
Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.
-
Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.
-
Apparatus
"New 'Breakthrough' Alzheimer's Drug Approved: Slows Brain Decline By 27%, But $26,500/Year Pricing Controversial
Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.
-
The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.
-
The "me better" strategy has always been a great story for pharmaceutical companies.